Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using this regimen was obtained mostly from Western breast cancer patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chang Gon, Sohn, Joohyuk, Chon, Hongjae, Kim, Joo Hoon, Heo, Su Jin, Cho, Hyunsoo, Kim, In Jung, Kim, Seung Il, Park, Seho, Park, Hyung Seok, Kim, Gun Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822110/
https://www.ncbi.nlm.nih.gov/pubmed/27064666
http://dx.doi.org/10.4048/jbc.2016.19.1.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822110/
https://www.ncbi.nlm.nih.gov/pubmed/27064666
http://dx.doi.org/10.4048/jbc.2016.19.1.76

Ejemplares similares